Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biomet CEO quits

This article was originally published in The Gray Sheet

Executive Summary

After nearly 20 years at the orthopedics firm, CEO and co-founder Dane Miller, PhD, resigned on March 27. Effectively immediately, Senior VP Daniel Hann, who joined the company in 1989, will command the top spot following Miller's departure. Miller will remain director of the board and will serve as a consultant to the company. "I'm not out of the game, just sitting on the bench right beside our new coach," Miller said during a March 27 call. Miller has served as CEO of the firm since its formation in 1977 and the decision was unexpected by many in the industry, especially after Miller headlined the Biomet's AAOS presentation just the week prior. However, it appears that several months of declines in both stock price and revenue growth likely forced his decision (1"The Gray Sheet" March 27, 2006, p.13)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel